{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab-relatlimab FDC"]],"indication":"later-line MSS metastatic colorectal cancer","name":"RELATIVITY-123","nct_id":"NCT05328908","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=relativity-123-nct05328908. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RELATIVITY-123","arms":[{"description":null,"label":"Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)","type":"EXPERIMENTAL"},{"description":"Treatment with Regorafenib or TAS-102","label":"Arm B: Investigator's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-07-14","type":"ACTUAL"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":769,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab-relatlimab FDC","otherNames":["BMS-986213"],"type":"DRUG"},{"name":"Regorafenib","otherNames":["Stivarga"],"type":"DRUG"},{"name":"TAS-102","otherNames":["Trifluridine/Tipiracil","Lonsurf"],"type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From date of randomization to the date of death due to any cause (Up to approxaimtely 38 months)"}],"references":[],"start_date":{"date":"2022-04-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT05328908"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/relativity-123-nct05328908"}